Jackson Laboratory

CD34+ Humanized NSG-FLT3 Mice

Females

Stock No: 703367 | NSG-FLT3

Contact: orderquest@jax.org | 1.800.422.6423 (US) | 1.207.288.5845 (International)

Overview

NSG-FLT3 Mouse - The Jackson Laboratory

The NSG-FLT3 mouse model is a comprehensive myeloid cell model following CD34 humanization. This transgenic mouse model has had the endogenous mouse Flt3 receptor knocked out and a human FLT3 ligand expressing transgene knocked in, a critical ligand for immune cell development. Human CD34 hematopoietic stem cell engrafted NSG-FLT3 mice express a diverse set of myeloid cell lineages such as CD33+ myeloid progenitors, CD14+ monocytes, and both functional CD11c+ conventional and CD123+ plasmacytoid dendritic cells. Off-the-shelf female mice are available at 18 to 24 weeks of age.

Key Benefits

CD34+ engrafted NSG-FLT3 mice have high levels of T cells, Tregs, CD33+ myeloid cells, CD14+ monocytes, and CD56^bright+/CD16- natural killer cells.
CD34+ engrafted NSG-FLT3L mice develop functionally active CD11c+ conventional and CD123+ plasmacytoid dendritic cells.
Readily engraftable with human cancer cell line derived and patient derived xenograft for preclinical therapeutic studies.

Order Now

Research Applicatons

Immuno-oncology	Autoimmune Disorders
Human Immune Function	Infectious Disease
Diabetes	Oncology
Stem Cell Biology

CD34+ hu-NSG-FLT3 mice improve frequency of human dendritic cells and develop higher levels of human CD14 monocytes & CD33 myeloid cells

Appearance & Care

CD34+ hu-NSG-FLT3 Mouse - The Jackson Laboratory

While CD34+ hematopoietic stem cell humanized mice do have a human-like immune system on-board, it is not fully functional. These mice should still be handled very carefully and treated as an immuno-deficient strain. We are glad to offer the following resources to help you care for highly immuno-deficient strains like NSG™. Additionally, you should be sure to check with your institution regarding requirements for housing mice with engrafted human tissue.

Animal Health Reports

RB11 (Maximum)

Phenotype Information

CD34 humanized NSG-FLT3 mice demonstrate presence of CD45 cells following engraftment, compared to NSG and NSG-SGM3 strains

CD34 humanized NSG-FLT3 mice demonstrate elevated levels of CD33+ myeloid progenitors after engraftment, compared to NSG and NSG-SGM3 strains

CD34 humanized NSG-FLT3 mice demonstrate elevated levels of CD14+ monocytes after engraftment, compared to NSG and NSG-SGM3 strains

Figure 1. CD34 humanized NSG-FLT3 mice demonstrate presence of CD45 cells (left) and elevated levels of CD33+ myeloid progenitors (center) and CD14+ monocytes (right) following engraftment as compared to NSG and NSG-SGM3 strains.

CD34 humanized NSG-FLT3 mice show elevated levels of CD3+ T cells following engraftment as compared to the NSG strain

CD34 humanized NSG-FLT3 mice show elevated levels of immature natural killer cells after engraftment, compared to the NSG strain

Figure 2. CD34 humanized NSG-FLT3 mice elevated levels of CD3+ T cells (left) and immature natural killer cells (right) following engraftment as compared to the NSG strain.

Figure 3. CD34 humanized NSG-FLT3 demonstrate increased presence of conventional dendritic cells following engraftment.

NSG-FLT3 mice demonstrate TNF cytokine release after innervation of TLR4 LPS receptors following immuno-stimulation

NSG-FLT3 mice demonstrate TNF cytokine release after innervation of TLR3 Poly I:C receptors following immuno-stimulation

NSG-FLT3 mice demonstrate TNF cytokine release after innervation of TLR9 CpG receptors following immuno-stimulation

NSG-FLT3 mice demonstrate IL12p40 cytokine release after innervation of TLR4 LPS receptors following immuno-stimulation

NSG-FLT3 mice demonstrate IL12p40 cytokine release after innervation of TLR3 Poly I:C receptors following immuno-stimulation

NSG-FLT3 mice demonstrate IL12p40 cytokine release after innervation of TLR9 CpG receptors following immuno-stimulation

Figure 4. NSG-FLT3 mice demonstrate TNF and IL12p40 cytokine release following innervation of TLR4 (LPS, left column), TLR3 (Poly I:C, center column), and TLR9 (CpG, right column) receptors following immuno-stimulation.

CD34 humanized NSG-FLT3 successfully engraft patient-derived PS4050 melanoma

CD34 humanized NSG-FLT3 successfully engraft patient-derived PS4050 melanoma and demonstrate infiltration of T cells in the tumor

CD34 humanized NSG-FLT3 successfully engraft patient-derived PS4050 melanoma and demonstrate infiltration of conventional dendritic cells in the tumor

CD34 humanized NSG-FLT3 successfully engraft patient-derived PS4050 melanoma and demonstrate infiltration of plasmacytoid dendritic cells in the tumor

CD34 humanized NSG-FLT3 successfully engraft patient-derived PS4050 melanoma and demonstrate infiltration of monocytes/macrophages in the tumor

CD34 humanized NSG-FLT3 successfully engraft patient-derived PS4050 melanoma and demonstrate infiltration of polarized M1 cells in the tumor

CD34 humanized NSG-FLT3 successfully engraft patient-derived PS4050 melanoma and demonstrate infiltration of polarized M2 cells in the tumor

Figure 5. CD34 humanized NSG-FLT3 successfully engraft patient-derived PS4050 melanoma and demonstrate infiltration of T cells, conventional dendritic cells, plasmacytoid dendritic cells, monocytes/macrophages, and polarized M1/M2 cells in the implanted tumor.

References & Resources

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.